Black Diamond Therapeutics, Inc. Common Stock(BDTX)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

Snapshot
$1.71
After hours $1.70 +0.00%
52-Week Range
$1.60 – $4.94
YTD
-31.51%
IV Rank (30D)
56.41
Straddle Price
$0.80
P/C Vol Ratio
0.06
Market Cap
$0.1B
Fair Value
+50.0% vs price
Confidence: 28% Alpha Score: 1.09

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.51%
Beta vs SPY1.00
Cost of Equity (CAPM)10.01% (VRP-adj)
WACC10.42%
Volatility Risk Premium+56.3pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.0B
Return on Equity (TTM)-41.4%
Book / Price98.2% — banking bias active (P/B is primary)
Debt / Equity0.00
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$2.49 (Market Anchor value)
SMA 20 / Bollinger Mid$1.92
Bollinger Width / SMA202515.6% (drives anchor stability)
Net Debt$-0.0B
Market Cap$0B
Peers used for multiples: BIIB, MRNA, REGN (filtered from 8 ETF-co-members; sector bias active)
Blended Fair Value
$2.78
Current Price
$1.70
Deviation
+50.0%
Forward-Return Rank LONG gates ✓
?
Horizon Expected α z Pred Blended z Rank % Active?
21d -0.8% +1.27 +1.63 95.7% ACTIVE
42d -0.3% +1.91 +1.94 97.5% ACTIVE
63d +2.2% +2.19 +2.09 98.3% ACTIVE
Expected α = forward-return point estimate vs SPY (e.g., +7.5% means the predictor expects this stock to outperform SPY by 7.5% over that horizon). For SHORT direction the model uses a different ranking metric (conviction-weighted deviation, not the LGBM prediction); Expected α is shown for reference. flags rows where Expected α disagrees with the FV direction — two independent signals are in conflict; conviction is low even if rank looks extreme.
Forward-Return Rank. A proprietary ensemble of a machine-learning forward-return model and a conviction-weighted fundamental score, ranked cross-sectionally each day across the S&P 500 (and broader universes on the screener). Each stock is scored at three horizons (21/42/63 trading days). "Active" = top/bottom 5% AND all risk filters pass. Backtested mean alpha vs SPY on active picks: 21d LONG +13.4%, 63d +34.9% (S&P 500, walk-forward). Past performance is not indicative of future results.
Value vs momentum conflict ⚠. The "FV direction" (long/short) comes from the fundamentals-based engine — price vs intrinsic value. The "Expected α" comes from a separate machine-learning predictor trained on ~12 features (sector, options-implied move, beta, institutional flow, etc.). Sometimes the two disagree: a stock is overvalued by fundamentals but the predictor expects it to keep outperforming (sector or momentum tailwinds). When all 3 horizons disagree, treat the direction signal as low-conviction — neither model is strongly recommending a position.
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0%
Peer EV/EBITDA n/a 0%
Peer P/B $3.76 23% median 2.1× · 3 peers
Peer P/S n/a 0% median 4.3× · 3 peers
Market Anchor (SMA50) $2.49 77% stability 65% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-06-25 · updated 2026-06-25 20:21:31.254000
Info
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836)
Exchange
XNAS
Market Cap
$0.1B

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) …

Chart
Seasonality
MonthAvg ReturnYears of Data
Jan +16.02% 6
Feb -7.86% 6
Mar -2.82% 6
Apr +2.54% 6
May +1.32% 6
Jun +32.28% 6
Jul +6.25% 5
Aug -0.99% 5
Sep -12.81% 5
Oct -7.73% 5
Nov -4.34% 5
Dec -10.15% 5
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators
SMA 20: $1.89
SMA 50: $2.47
SMA 200: $2.86
Current: $1.70
EMA 12: $1.79
EMA 26: $2.01
MACD: -0.2292 | Signal: 0.0121
BEARISH
ADX (14): 23.21
WEAK TREND
+DI: 19.85
−DI: 25.23
Momentum Oscillators
RSI (14): 37.47
NEUTRAL
Stoch %K: 20.84
Stoch %D: 12.69
Williams %R: -81.73
Volume & Volatility
BB Upper: $2.32
BB Lower: $1.45
NEUTRAL
OBV: 63,778,182
Vol SMA 20: 1,616,177
Vol ROC: 4.41%
ATR: $0.19
True Range: $0.20
HV 20: 73.8%
HV 30: 160.3%
HV 60: 126.0%

Data Summary
Data Points: 500
Last Updated: 2026-06-25T19:55:14.052000
Date Range: 2024-06-26T00:00:00 – 2026-06-24T00:00:00
AI Analysis

Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

News
Earnings History
7 of 7 under expected move
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-08-06 Pre-Market 20.33% 8.69% 0.43x Within
2024-11-05 After-Close 41.67% 3.46% 0.08x Within
2025-05-12 After-Close 42.98% 9.74% 0.23x Within
2025-08-07 After-Close 19.74% 5.26% 0.27x Within
2025-12-03 Pre-Market 236.63% 30.11% 0.13x Within
2026-03-16 After-Close 31.01% 2.44% 0.08x Within
2026-05-07 After-Close 17.46% 9.96% 0.57x Within
Options Activity
IV Rank (30D)
56.41
IV Rank (7D)
56.41
Avg IV
270.6%
Straddle (30D)
$0.80
Straddle (7D)
$0.80
P/C Volume
0.06
Spread Scanner GPU

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
pts EXTREME
ATM — / Wing —
30 DTE / 10d
pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
2.12
Correlation (SPY)
31.0%
0.10
Ann. Volatility
85.2%
SPY Volatility
12.5%

High volatility - stock moves more than market

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-03-31
Diluted shares outstanding: 57,132,178 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

109 filers81,037,471 shares$118.41M value141.84% of float
# Filer Shares Value % of Total % of Float Period
1 NEA Management Company, LLC 8,897,514 $18.95M 16.01% 15.57% 2026-03-31
2 VANGUARD GROUP INC Custodian 4,377,714 $10.64M 8.98% 7.66% 2025-12-31
3 VANGUARD CAPITAL MANAGEMENT LLC 3,700,936 $7.88M 6.66% 6.48% 2026-03-31
4 RENAISSANCE TECHNOLOGIES LLC 3,287,494 $7.00M 5.91% 5.75% 2026-03-31
5 DIMENSIONAL FUND ADVISORS LP Custodian 2,603,328 $5.54M 4.68% 4.56% 2026-03-31
6 BlackRock, Inc. Custodian 2,213,680 $4.72M 3.98% 3.87% 2026-03-31
7 Connor, Clark & Lunn Investment Management Ltd. 2,116,794 $4.51M 3.81% 3.71% 2026-03-31
8 MACKENZIE FINANCIAL CORP 1,689,670 $3.60M 3.04% 2.96% 2026-03-31
9 MARSHALL WACE, LLP Custodian 1,672,532 $3.56M 3.01% 2.93% 2026-03-31
10 ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 1,669,140 $3.56M 3.00% 2.92% 2026-03-31
11 BRIDGEWAY CAPITAL MANAGEMENT, LLC 1,446,954 $3.08M 2.60% 2.53% 2026-03-31
12 GOLDMAN SACHS GROUP INC Custodian 1,368,836 $2.92M 2.46% 2.40% 2026-03-31
13 FMR LLC Custodian 1,247,654 $2.66M 2.24% 2.18% 2026-03-31
14 UBS Group AG Custodian 1,129,676 $2.41M 2.03% 1.98% 2026-03-31
15 Man Group plc 1,119,400 $2.38M 2.01% 1.96% 2026-03-31
16 WINTON GROUP Ltd 1,076,518 $2.29M 1.94% 1.88% 2026-03-31
17 GEODE CAPITAL MANAGEMENT, LLC Custodian 1,073,150 $2.29M 1.93% 1.88% 2026-03-31
18 AWM Investment Company, Inc. 1,050,000 $2.24M 1.89% 1.84% 2026-03-31
19 BALYASNY ASSET MANAGEMENT L.P. 1,021,622 $2.18M 1.84% 1.79% 2026-03-31
20 CITADEL ADVISORS LLC Custodian 1,005,304 $2.14M 1.81% 1.76% 2026-03-31
21 NORTHERN TRUST CORP Custodian 929,416 $1.98M 1.67% 1.63% 2026-03-31
22 D. E. Shaw & Co., Inc. Custodian 727,842 $1.55M 1.31% 1.27% 2026-03-31
23 GLOBEFLEX CAPITAL L P 610,552 $1.30M 1.10% 1.07% 2026-03-31
24 STIFEL FINANCIAL CORP Custodian 557,290 $1.19M 1.00% 0.98% 2026-03-31
25 VANGUARD FIDUCIARY TRUST CO 519,816 $1.11M 0.94% 0.91% 2026-03-31
5 filers$348.89K notional
# Filer Notional Value % of Total Period
1 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $114.59K 32.84% 2026-03-31
2 GROUP ONE TRADING LLC Custodian $96.28K 27.59% 2026-03-31
3 JANE STREET GROUP, LLC Custodian $77.96K 22.34% 2026-03-31
4 CITADEL ADVISORS LLC Custodian $46.86K 13.43% 2026-03-31
5 SIMPLEX TRADING, LLC Custodian $13.21K 3.79% 2026-03-31
3 filers$438.99K notional
# Filer Notional Value % of Total Period
1 CITADEL ADVISORS LLC Custodian $387.23K 88.21% 2026-03-31
2 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $48.56K 11.06% 2026-03-31
3 SIMPLEX TRADING, LLC Custodian $3.19K 0.73% 2026-03-31
Insider Activity
Latest: 2026-06-22
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-06-22 Prakash Raman Director Award (A) +7,907 $1.66 $13.1K EDGAR
2026-06-22 Ali Behbahani Director Award (A) +8,961 $1.66 $14.9K EDGAR
2026-03-20 Prakash Raman Director Award (A) +6,105 $2.15 $13.1K EDGAR
2026-03-20 Ali Behbahani Director Award (A) +6,919 $2.15 $14.9K EDGAR
2026-01-23 Mark A. Velleca PRESIDENT & CEO Grant (A) +600,000 opt EDGAR
2026-01-23 Elizabeth Buck CHIEF SCIENTIFIC OFFICER Grant (A) +250,000 opt EDGAR
2026-01-23 Erika Jones SEE REMARKS Grant (A) +200,000 opt EDGAR
2026-01-23 Sergey Yurasov CHIEF MEDICAL OFFICER Grant (A) +250,000 opt EDGAR
2026-01-23 Brent Hatzis-Schoch SEE REMARKS Grant (A) +250,000 opt EDGAR
2025-12-15 Prakash Raman Director Award (A) +4,665 $2.76 $12.9K EDGAR
2025-12-15 Ali Behbahani Director Award (A) +5,208 $2.76 $14.4K EDGAR
2025-09-22 Prakash Raman Director Award (A) +3,843 $3.35 $12.9K EDGAR
2025-09-22 Ali Behbahani Director Award (A) +4,291 $3.35 $14.4K EDGAR
2025-06-20 Ali Behbahani Director Award (A) +6,170 $2.33 $14.4K EDGAR
2025-06-20 Prakash Raman Director Award (A) +5,526 $2.33 $12.9K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
26 insiders · @ $1.70
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 GROWTH N V BIOTECH 10%+ Owner 8,517,839 $14.44M $1.87M 1 2023-10-19
2 BB BIOTECH AG 10%+ Owner 7,517,839 $12.74M $13.50M 10 2025-03-20
3 Versant Voyageurs I Parallel, L.P. 10%+ Owner 6,365,666 $10.79M -$8.49M 4 2020-11-19
4 Versant Voyageurs I, L.P. 10%+ Owner 5,225,482 $8.86M -$4.28M 4 2020-12-16
5 Ali Behbahani Director 4,551,286 $7.71M $20.20M 28 2026-06-22
6 Versant Venture Capital VI, L.P. 10%+ Owner 4,343,210 $7.36M $39.27M 9 2020-11-25
7 Versant Vantage I, L.P. 10%+ Owner 4,107,283 $6.96M -$10.78M 5 2024-08-30
8 RA Capital Healthcare Fund LP Director 3,213,828 $5.45M $23.40M 1 2023-07-07
9 DEERFIELD MANAGEMENT COMPANY, L.P. 10%+ Owner 778,790 $1.32M $30.40M 1 2020-02-03
10 David M. Epstein SEE REMARKS 694,513 $1.18M -$1.67M 11 2023-06-28
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
Notice of Proposed Sale (Form 144)
Latest: 2024-07-31
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.

Source & freshness: Parsed directly from EDGAR primary-doc XML. Daily refresh; new filings typically appear here the morning after they hit EDGAR.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2024-07-31 David Epstein Former Employer 50,000 $310.0K 2024-07-31 UBS Financial Services Inc EDGAR
2024-07-26 David Epstein Former Employee 50,000 $310.0K 2024-07-26 UBS Financial Services Inc EDGAR
2024-07-16 David Epstein Former Employer 50,000 $312.5K 2024-07-16 UBS Financial Services Inc EDGAR
2024-07-11 David Epstein Former Employer 69,024 $345.1K 2024-07-11 UBS Financial Services Inc EDGAR
2024-07-09 David Esptein Former Employee 75,000 $360.0K 2024-07-09 UBS Financial Services Inc EDGAR
2024-06-28 David Epstein Former Employer 50,000 $250.0K 2024-06-28 UBS Financial Services Inc EDGAR
2024-06-27 David Epstein Former Board Member 40,353 $189.7K 2024-06-27 UBS Financial Services Inc EDGAR
2024-06-26 David Epstein Former Board Member 9,647 $45.3K 2024-06-26 UBS Financial Services Inc EDGAR
2024-06-24 David Epstein Former Board Member 6,011 $30.2K 2024-06-24 UBS Financial Services Inc EDGAR
2024-06-21 David Epstein Former Board Member 743 $3.7K 2024-06-21 UBS Financial Services Inc EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed.
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

P/B Ratio0.9
EV/EBITDA-1.4
TTM Net Income$-0.0B
TTM EPS$-0.76
ROE-41.4%